Neurofilament light and heterogeneity of disease progression in amyotrophic lateral sclerosis: development and validation of a prediction model to improve interventional trials.

Simon WitzelFelix FrauhammerPetra SteinackerDavid DevosPierre-François PradatVincent MeiningerSteffen HalbgebauerPatrick OecklJoachim SchusterSimon AndersJohannes DorstMarkus OttoAlbert C Ludolph

Published in: Translational neurodegeneration (2021)

The use of the NfL-based prediction model to compensate for clinical heterogeneity in ALS could significantly increase the trial power. NCT00868166, registered March 23, 2009; NCT02306590, registered December 2, 2014.

Keyphrases

single cell
study protocol
clinical trial
cerebrospinal fluid
phase iii
phase ii
randomized controlled trial